C. R. M. Hay

11.2k total citations
176 papers, 7.6k citations indexed

About

C. R. M. Hay is a scholar working on Hematology, Genetics and Genetics. According to data from OpenAlex, C. R. M. Hay has authored 176 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Hematology, 40 papers in Genetics and 26 papers in Genetics. Recurrent topics in C. R. M. Hay's work include Hemophilia Treatment and Research (100 papers), Platelet Disorders and Treatments (56 papers) and Blood Coagulation and Thrombosis Mechanisms (51 papers). C. R. M. Hay is often cited by papers focused on Hemophilia Treatment and Research (100 papers), Platelet Disorders and Treatments (56 papers) and Blood Coagulation and Thrombosis Mechanisms (51 papers). C. R. M. Hay collaborates with scholars based in United Kingdom, United States and Italy. C. R. M. Hay's co-authors include Peter W. Collins, Donna DiMichele, David Keeling, Ri Liesner, Kevin Docherty, Aura S. Kamiguti, Mirko Zuzel, Claude Négrier, A. M. Cumming and Simon Brown and has published in prestigious journals such as The Lancet, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

C. R. M. Hay

172 papers receiving 7.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. R. M. Hay United Kingdom 47 5.6k 1.7k 1.4k 1000 756 176 7.6k
Guido Tans Netherlands 37 4.1k 0.7× 1.5k 0.9× 629 0.5× 870 0.9× 355 0.5× 93 5.4k
L Degos France 43 3.6k 0.6× 681 0.4× 3.4k 2.5× 1.1k 1.1× 360 0.5× 193 6.9k
Edward G. D. Tuddenham United Kingdom 61 8.5k 1.5× 2.5k 1.5× 3.8k 2.8× 2.1k 2.1× 895 1.2× 251 13.5k
Peter Bettelheim Austria 40 2.1k 0.4× 1.1k 0.7× 1.2k 0.9× 319 0.3× 252 0.3× 153 5.7k
David B. Miklos United States 37 2.1k 0.4× 777 0.5× 1.5k 1.1× 810 0.8× 308 0.4× 224 6.5k
Bruce M. Ewenstein United States 49 4.7k 0.8× 1.5k 0.9× 1.3k 0.9× 401 0.4× 696 0.9× 149 6.9k
Alessandro Pileri Italy 44 4.1k 0.7× 1.6k 0.9× 2.1k 1.5× 346 0.3× 248 0.3× 335 8.2k
Claus R. Bartram Germany 48 4.1k 0.7× 2.1k 1.3× 3.8k 2.8× 1.3k 1.3× 258 0.3× 212 10.0k
Alain Bernheim France 47 1.7k 0.3× 1.1k 0.7× 2.9k 2.1× 1.3k 1.3× 836 1.1× 287 8.4k
John Koreth United States 51 5.9k 1.1× 1.4k 0.8× 1.4k 1.0× 412 0.4× 400 0.5× 199 9.3k

Countries citing papers authored by C. R. M. Hay

Since Specialization
Citations

This map shows the geographic impact of C. R. M. Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. R. M. Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. R. M. Hay more than expected).

Fields of papers citing papers by C. R. M. Hay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. R. M. Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. R. M. Hay. The network helps show where C. R. M. Hay may publish in the future.

Co-authorship network of co-authors of C. R. M. Hay

This figure shows the co-authorship network connecting the top 25 collaborators of C. R. M. Hay. A scholar is included among the top collaborators of C. R. M. Hay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. R. M. Hay. C. R. M. Hay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiang, Hua, Ben Palmer, Pratima Chowdary, et al.. (2025). Emicizumab utilization, safety, and outcomes in people with severe hemophilia and no inhibitors: 3-year follow-up. A report from the UK Haemophilia Centre Doctors’ Organisation. Research and Practice in Thrombosis and Haemostasis. 9(6). 103164–103164.
2.
Oldenburg, Johannes, C. R. M. Hay, Flora Peyvandi, et al.. (2024). Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half‐Life FVIII in Hemophilia A: A‐SURE Study. European Journal Of Haematology. 114(2). 248–257.
3.
Bagot, Catherine, Erik A.M. Beckers, Giancarlo Castaman, et al.. (2022). The bleeding phenotype in people with nonsevere hemophilia. Blood Advances. 6(14). 4256–4265. 17 indexed citations
4.
Hart, Daniel P., Jayanthi Alamelu, Neha Bhatnagar, et al.. (2021). Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia. 27(6). 932–937. 17 indexed citations
5.
Peyvandi, Flora, Johnny Mahlangu, Steven W. Pipe, et al.. (2020). Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. Journal of Thrombosis and Haemostasis. 19. 32–41. 14 indexed citations
6.
Scott, M.J., C. R. M. Hay, Peter W. Collins, et al.. (2020). A WITHIN-PATIENT COMPARISON OF EFFICACY AND OUTCOME OF RECOMBINANT FIX AND FIXFC IN HAEMOPHILIA B IN THE UK. Haemophilia. 26. 63–64. 2 indexed citations
7.
Gruppo, Ralph A., Daniel R Malan, J. Kapocsi, et al.. (2018). Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis. 16(10). 1984–1993. 17 indexed citations
8.
9.
Collins, Peter W., Elizabeth Chalmers, Daniel P. Hart, et al.. (2014). Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood. 124(23). 3389–3397. 81 indexed citations
10.
Velzen, Alice S. van, Corien L. Eckhardt, Matthew Peters, et al.. (2013). Inhibitor eradication therapy in non-severe hemophilia A. Journal of Thrombosis and Haemostasis. 11. 207–207. 1 indexed citations
11.
Hay, C. R. M., Angela E. Taylor, Anna Wingate, et al.. (2012). Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. Cancer Research. 72(9). 2176–2182. 201 indexed citations
12.
Forsyth, Angela, Paul Giangrande, C. R. M. Hay, et al.. (2012). Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia. 18(s5). 39–45. 4 indexed citations
13.
Hay, C. R. M. & Donna DiMichele. (2011). The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 119(6). 1335–1344. 322 indexed citations
14.
Hay, C. R. M., Ben Palmer, Elizabeth Chalmers, et al.. (2011). Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood. 117(23). 6367–6370. 140 indexed citations
15.
Hay, C. R. M., et al.. (2007). Purpura fulminans in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 137(4). 271–271. 8 indexed citations
16.
Bernardo, Andreia S., John Barrow, C. R. M. Hay, et al.. (2006). Presence of endocrine and exocrine markers in EGFP-positive cells from the developing pancreas of a nestin/EGFP mouse. Molecular and Cellular Endocrinology. 253(1-2). 14–21. 13 indexed citations
17.
Berntorp, Erik, Jan Astermark, V. Blanchette, et al.. (2006). Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia. 12(s6). 1–7. 82 indexed citations
18.
Darby, Stephen E., David Keeling, Rosemary J. D. Spooner, et al.. (2004). The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. Journal of Thrombosis and Haemostasis. 2(7). 1047–1054. 211 indexed citations
19.
Hay, C. R. M., Trevor Baglin, P. Collins, F. G. H. Hill, & David Keeling. (2000). The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). British Journal of Haematology. 111(1). 78–90. 108 indexed citations
20.
Hay, C. R. M.. (1988). Mathematics from manuscript to print, 1300-1600. Oxford University Press eBooks. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guido Tans Breakdown of academic impact, for papers by L Degos Breakdown of academic impact, for papers by Edward G. D. Tuddenham Breakdown of academic impact, for papers by Peter Bettelheim Breakdown of academic impact, for papers by David B. Miklos Breakdown of academic impact, for papers by Bruce M. Ewenstein Breakdown of academic impact, for papers by Alessandro Pileri Breakdown of academic impact, for papers by Claus R. Bartram Breakdown of academic impact, for papers by Alain Bernheim Breakdown of academic impact, for papers by John Koreth
Rankless by CCL
2026